Novartis pelacarsen misses Phase 3 primary endpoint versus placebo
Novartis said pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce the risk of cardiovascular events versus placebo, including deaths, heart attacks and strokes.
Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study. The company said on Friday that pelacarsen did not reduce the risk of cardiovascular events, including deaths, heart attacks and strokes, versus placebo. The drug did succeed…